Ekso Bionics Reports Q2 Revenue Drop Amid Sales Delays, Sees Growth Ahead

Ekso Bionics reported a 58% decrease in Q2 revenue to $2.06 million due to sales delays. CEO Scott Davis expects recovery in the latter half of the year and growth in the Personal Health segment. Wall Street analysts forecast an average target price of $37.50 with a high estimate of $60.00 and a low estimate of $15.00. The average target implies an upside of 727.81% from the current price.

Marin County-based medical technology company Ekso Bionics reported a challenging second quarter, with revenues dropping to $2.1 million for the period ended June 30, down from $5 million a year earlier. The net loss for the quarter was $2.7 million, compared to $2.4 million in the same period last year [1, 2, 3]. CEO Scott Davis attributed the revenue shortfall to short-term delays in completing two significant sales of multiple devices with healthcare enterprises.

Despite the revenue challenges, Ekso Bionics remains optimistic about future prospects. The company sees growing potential in its Personal Health segment, specifically the Ekso Indigo personal exoskeleton, a robotic mobility device. Personal health product revenues grew more than 50% in the first six months of 2025, with expectations of reaching 25% of total company revenue this year [1, 2]. The company noted several key developments during the quarter, including partnering with PREA Healthcare to navigate market access complexities, receiving the first order from National Seating & Mobility, and joining the NVIDIA Connect program to develop artificial intelligence capabilities for exoskeleton technology [1, 2, 3].

The company's cash position stood at $5.2 million as of June 30, 2025. Wall Street analysts forecast an average target price of $37.50, with a high estimate of $60.00 and a low estimate of $15.00 [4]. The average target price implies an upside of 727.81% from the current price.

Ekso Bionics expects to close significant deferred multi-device Enterprise Health sales by year-end, which could help improve its financial performance. The company has developed a pipeline of over 45 Medicare beneficiaries qualified for the Ekso Indigo personal exoskeleton, a 200% increase from the end of last year [1, 2, 3].

Founded two decades ago, Ekso Bionics moved from the East Bay to Marin in 2022. The company is focused on developing and commercializing advanced robotic mobility devices for medical and personal use [1, 2, 3].

References:
[1] https://www.northbaybusinessjournal.com/article/article/ekso-bionics-q2-2025/
[2] https://www.ainvest.com/news/ekso-bionics-holdings-ekso-q2-2025-earnings-call-highlights-navigating-revenue-decline-launch-eksouniversity-partnership-pria-healthcare-2507/
[3] https://www.pressdemocrat.com/article/north-bay/ekso-bionics-q2-2025/?ref=home-business
[4] https://www.marketbeat.com/stocks/NASDAQ/EKSO/news/